Table 2.
Treatment and outcomes at 1 year (n = 82)
| Induction therapy, n (%) | |
| Prednisone | 82 (100) |
| Pulse methylprednisolone | 63 (77) |
| Plasma exchange | 15 (18) |
| Additional immunosuppressive treatments | 82 (100) |
| Cyclophosphamide | 73 (89) |
| Cyclophosphamide and Rituximab | 3 (3.6) |
| % i.v./p.o. cyclophosphamide | 37, 52 |
| Duration of cyclophosphamide (mo) | 6 (4–10) |
| Rituximab | 4 (4.9) |
| Methotrexate | 1 (1.2) |
| Azathioprine | 1 (1.2) |
| Maintenance therapy, n (%) | |
| Rituximab/cyclophosphamide → azathioprine | 3 (3.6) |
| Rituximab → azathioprine | 2 (2.4) |
| Cyclophosphamide → methotrexate | 5 (6.1) |
| Cyclophosphamide → azathioprine | 42 (51) |
| Cyclophosphamide → rituximab | 2 (2.4) |
| Cyclophosphamide → mycophenolate mofetil | 1 (1.2) |
| No change | 27 (33) |
| Outcomes | |
| Change in GFR at 12 months (ml/min per 1.73 m2) | +15 ± 20 |
| Relapse, n (%) | 1 (2.4) |
| Required dialysis during the 1st year, n (%) | 21 (26) |
| Recovery from dialysis, n (% of those with dialysis) | 12 (57) |
All received corticosteroids and an additional immunosuppressant and completed at least 1 year of follow-up.
→, changed to; GFR, glomerular filtration rate.